

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 4 : A01N 59/12	A1	(11) International Publication Number: WO 89/ 00006 (43) International Publication Date: 12 January 1989 (12.01.89)
(21) International Application Number: PCT/AU88/00234 (22) International Filing Date: 1 July 1988 (01.07.88) (31) Priority Application Number: PI 2820 (32) Priority Date: 1 July 1987 (01.07.87) (33) Priority Country: AU (71) Applicant (for all designated States except US): NOVA-PHARM RESEARCH PTY. LTD. [AU/AU]; 1 Thew Parade, Dee Why, NSW 2099 (AU). (72) Inventor; and (75) Inventor/Applicant (for US only) : GLUCK, Bruno, Anthony [AU/AU]; 1 Thew Parade, Dee Why, NSW 2099 (AU). (74) Agent: SPRUSON & FERGUSON; G.P.O. Box 3898, Sydney, NSW 2001 (AU).		(81) Designated States: AT (European patent), AU, BE (European patent), BR, CH (European patent), DE (European patent), DK, FI, FR (European patent), GB (European patent), IT (European patent), JP, KR, LU (European patent), NL (European patent), NO, SE (European patent), US. Published <i>With international search report.</i>
(54) Title: BIOCIDAL COMPOSITION (57) Abstract <p>The present invention provides a stable organic iodophor composition comprising an iodophor wherein the ratio of organic iodine solubilizing compound to iodine is less than 5:1 and containing between 10 and 60 % by weight of an iodine liberating substance. The invention also provides a process for the production of an iodophor composition which process comprises dissolving an organic iodine solubilizing compound and iodine or an iodine liberating substance in water in amounts such that the ratio of iodine liberating substance to iodine is less than 5:1 by weight and optionally adjusting the pH, adding an oxidizing agent and readjusting the pH following oxidation.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	ML	Mali
AU	Australia	GA	Gabon	MR	Mauritania
BB	Barbados	GB	United Kingdom	MW	Malawi
BE	Belgium	HU	Hungary	NL	Netherlands
BG	Bulgaria	IT	Italy	NO	Norway
BJ	Benin	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	LI	Liechtenstein	SN	Senegal
CH	Switzerland	LK	Sri Lanka	SU	Soviet Union
CM	Cameroon	LU	Luxembourg	TD	Chad
DE	Germany, Federal Republic of	MC	Monaco	TG	Togo
DK	Denmark	MG	Madagascar	US	United States of America
FI	Finland				

- 1 -

BIOCIDAL COMPOSITIONTECHNICAL FIELD

The present invention relates to iodophor germicidal compositions and more particularly to the production of low cost iodophor germicidal compositions of improved stability by virtue of their unusually low PVP:I₂ ratios.

BACKGROUND ART

There has been in the past a continuing effort to develop a germicidal composition which is stable and cheap to manufacture.

10 The advantages of iodine condensed with a carrier, known as an iodophor and resulting in complex formation, over previously used iodine preparations such as Tincture of iodine and Lugol's solution are well documented.

The art is rich in attempts to efficiently produce an iodophor complex which is both cheap to prepare and stable over a period of time.

It was previously believed that such compositions needed a high PVP:I₂ ratio for stability.

20 For example in US Patent 3 028 300 iodine and iodide are combined directly with polyvinylpyrrolidone, hereinafter known as PVP, in the dry state. US 3 028 300 teaches that the PVP to iodine ratio must be at least 3:1 and the iodide to iodine ratio greater than 0.5. The disadvantage with this process is that the stability of the complex form decreases with decreasing proportions of PVP as shown in the tables illustrating the invention. No complex can be formed when the PVP to iodine is less than 3:1.

30 The process of US Patent 4 113 857 also uses for the iodine complex formation, oxidation of an iodine containing substance by an oxidising medium but with the following significant important difference to the present invention, namely the use of an excess of oxidising agent such as hydrogen peroxide or potassium iodate which leaves the final product free of iodide, claimed to be an essential and integral part of the invention. In contrast the present invention requires at least 10% of iodide calculated on the iodine of the complex.

US Patent 4 320 114 discloses a PVP-iodine complex wherein the complex is formed by combining, eg KI, PVP, and hydrogen peroxide. The pH is adjusted to between 2 and 7. The iodine is formed in situ by adding an oxidizing agent for partially converting the iodide ions into free iodine.

German Patent 27 18 385 discloses a process for forming a PVP-iodine complex by incomplete oxidation of iodide 4) and a ratio of PVP:iodine of

- 2 -

approximately 5:1.

Spanish Patents 545 377 and 86-08317 disclose PVP-iodine complexes formed with a 10% excess of KIO_3 . Complete oxidation of the iodide would be expected. The ratio of PVP:iodine is 10:1.

United Kingdom Patent 2 084 875 discloses a composition in dry form, to be dissolved in water shortly before use. The iodophor is formed after dissolution in water. The ratios claimed are broad. The example discloses a 2:1 weight ratio for the PVP:KI, but no or little excess iodide would be expected as the iodide and the perborate are added in approximately
10 equimolar amounts, based on the oxidizing strength of the perborate.

US Patents 3 898 326 and 4 017 407 provide iodine by direct addition.

US Patent 4 130 640 discloses a germicidal composition containing a sulfated fatty alcohol and/or a sulfosuccinates of a fatty alcohol in combination with PVP-iodine or iodine/iodide.

US Patent 4 402 937 requires that the ratio of iodine:iodide be about 2:1. The solution is stabilized with the addition of a reducing rather than an oxidizing agent which reduces iodine to iodide.

US Patent 4 526 751 discloses a weight ratio of about 2:1 for PVP:interhalogen solution and about 0.5:1 for iodide:iodine.

20 US Patent 4 038 476 discloses free-flowing granules of practically uniform composition and particle size consisting of PVP and iodide by combining with uniform thorough mixing a solution and/or colloidal suspension of a substance releasing iodide ions in a first solvent. The mixture as well as a solution and/or colloidal suspension and/or suspension of PVP in a second solvent or solvent mixture which possesses surface tension different from that of the first solvent or solvent mixture and in which PVP is at least partially soluble or wettable and in which the substance releasing iodide ions contained in the first solvent or solvent mixture is insoluble or only slightly soluble.

30 US Patent 4 125 602 is directed to the preparation of iodophor granules of practically uniform particle size consisting of PVP, iodine and a substance releasing iodide ions by combining with uniform thorough mixing a solution and/or colloidal suspension of elementary iodine and a substance releasing iodide ions in a first solvent or solvent mixture as well as a solution and/or colloidal solution and/or suspension of PVP in a second solvent or solvent mixture which has a surface tension different from that of the first solvent or solvent mixture and in which PVP is at least partially soluble or wettable and in which the substance is dissolved or

- 3 -

suspended in the first solvent or solvent mixture are insoluble or only slightly soluble and separating and drying the granules formed.

DISCLOSURE OF THE INVENTION

In accordance with one broad form of the invention there is provided a stable organic iodophor composition comprising an iodophor wherein the ratio of organic iodine solubilizing compound to iodine is less than 5:1 preferably containing between 10 and 60% by weight of an iodine liberating substance.

10 The organic iodine solubilizing compounds suitable for this invention can be selected from cationic surfactants, non-ionic surfactants, polymers such as PVP, and copolymers. Suitable cationic surfactants are quaternary ammonium salts. Suitable non-ionic surfactants have the general formula $RO(CH_2CH_2O)_nOH$ where R is nonylphenol, a fatty acid or fatty alcohol residue and where n is an integer greater than 3. The most preferred form of PVP is PVP K30.

Suitable iodine liberating substances include hydroiodic acid, and alkali metal iodides preferably potassium iodide.

20 In accordance with another broad form of the invention there is provided a process for the production of an iodophor of improved stability comprising the steps of dissolving an organic iodine solubilizing compound and an iodine liberating substance and an oxidising compound in water, adjusting the pH value for example by adding sufficient nonorganic or organic acid such as phosphoric-, sulphuric-, hydrochloric-, sulphamic- or oxalic-, citric- or lactic acid so that the pH after all the iodine has been complexed is below 7.0. The pH may be then adjusted with alkali or acid to the desired pH level preferably if PVP is the complexing substance, between 3.5 - 5.5 and in the case of a non-ionic below 2.5, depending on the application, and adding an oxidising agent.

30 Examples of suitable oxidising compounds are peroxides, such as hydrogen peroxide; iodates; and persulfates such as sodium, potassium or ammonium persulfates. It is preferred that hydrogen peroxide is used as an oxidising agent and that is used at a concentration of between 22.5% and 30%.

The invention is characterised by forming an iodophor through liberation of iodine from an iodine liberating substance by an oxidising agent in the presence of an organic iodine solubilising compound in the proportion of 5:1 or less and leaving an excess iodide. The iodophor, thus obtained, shows improved stability when the proportion of iodine to the

- 4 -

organic iodine complex forming substance is increased, contrary to what could be expected from the PVP:I complex prepared as described in the previous art.

For example a PVP-iodine complex where the proportion of PVP to iodine is 1.75:1 is significantly more stable than the complex where the proportion is 7:1. The latter proportion is the accepted value in commercially available PVP-iodine products.

It is obvious that the qualitative improvement of the iodophor obtained by the newly invented process, offers the additional advantage of cost savings by using only one fourth of the amount of PVP used in prior art processes.

In another broad form this invention provides a method for the antiseptic and disinfecting treatment of organic and inert surfaces requiring such treatment, which method comprises treating said object with an effective amount of the composition described above, for a period of time sufficient to effect desired asepsis.

BRIEF DESCRIPTION OF DRAWING

The drawing shows loss of available iodine in aqueous solutions containing the povidone iodine concentrates at various povidone to iodine ratios.

BEST MODES FOR CARRYING OUT THE INVENTION

The following examples illustrate preferred embodiments of the invention and should not be construed as limiting thereon.

EXAMPLE 1

PVP:I ratio 1.75:1

ANTISEPTIC TINCTURE (0.1% w/v AV. IODINE)

1.75g of PVP K30, 5g glycerol, and 1.1g of potassium iodide was dissolved in 100ml of water. Phosphoric acid (0.7ml, 85%), was then added with slow stirring, followed by 0.6ml of 27.5% hydrogen peroxide. The solution was allowed to stand for at least 12 hours and the pH adjusted using either phosphoric acid or sodium hydroxide to approximately 4.5. Ethyl alcohol, (700ml) was added and the volume adjusted with water, approx. 200ml, to give a final available iodine of 0.1%w/v.

EXAMPLE 2

PVP:I ratio 1.75:1

ANTISEPTIC OINTMENT (5% w/v IODINE)

A mixture of 72.5 gm of polyethyleneglycol 400 and 17.5 gm polyethyleneglycol 4000 is heated to approximately 45 to 50 degrees C with stirring. Heating is continued until a clear even liquid is obtained.

- 5 -

Then 10 gm with a PVP:I ratio of 1.75:1 and an available iodine content of 5% is slowly stirred in. Stirring is continued until an even product is obtained and then allowed to cool. An even smooth easily applied to the skin antiseptic is obtained.

EXAMPLE 3PVP:I ratio 5:1ANTISEPTIC SOLUTION (1% w/v AV. IODINE)

50g Polyvinylpyrrolidone K30 and 22g of potassium iodide was dissolved in 200ml of water. Phosphoric acid (7ml, 85%), was added with slow stirring followed by 6ml of 27.5% hydrogen peroxide. The solution was allowed to stand for at least 12 hours and the pH adjusted with either phosphoric acid or sodium hydroxide to approx. 4.5. Sufficient water, approx. 800ml, was added to give a final available iodine content of 1%w/v.

EXAMPLE 4PVP:I ratio 3:1TEAT DIP FOR MASTITIS CONTROL (0.5% w/v AV. IODINE)

15g of PVP K30, 50g of glycerol and 11g of potassium iodide was dissolved in 200ml of water. Phosphoric acid (3.5ml, 85%), was then added with slow stirring, followed by 3ml of 27.5% hydrogen peroxide. The solution was allowed to stand for at least 12 hours and the pH adjusted to approximately 4.5 with either phosphoric acid or sodium hydroxide. Sufficient water, approximately 800ml, was added to give a final available iodine content of 0.5%w/v.

EXAMPLE 5PVP:I ratio 3:1POVIDONE IODINE CONCENTRATE

150g of PVP K30 and 110g of potassium iodide was dissolved in 500ml of water. 35ml of 85% Phosphoric acid was then added with slow stirring followed by 30ml of 27.5% hydrogen peroxide. The solution was allowed to stand for at least 12 hours and the pH adjusted to approx. 4.5 with either phosphoric acid or sodium hydroxide. Sufficient water, approx. 175ml, was added to give a final available iodine content of 5.0%w/v.

The concentrate can be used as starting material for the manufacture of various antiseptic and disinfecting products for various applications and concentrations.

COMPARATIVE EXAMPLE 1EFFECT OF OXIDIZERS ON PVP-I STABILITY

Table I shows the effect of added oxidizers in excess of theoretical

- 6 -

quantity necessary to liberate all iodine from the iodine liberating substance on the stability of an aqueous PVP-I solution containing 1% available iodine. For all batches a PVP-I ratio of 7:1 was employed and all samples were stored at accelerated testing conditions of 55°C. The test solutions were stored in stoppered clear dark brown glass bottles. Aliquots were sampled at the intervals shown in the table and the concentration of iodine determined using the thiosulphate method.

TABLE 1: % AVAILABLE IODINE LOSS AT 55°C

	<u>OXIDIZER</u>	<u>5 DAYS</u>	<u>7 DAYS</u>	<u>14 DAYS</u>
10	Control	17.0 %	27.4 %	39.6 %
	Hydrogen peroxide)	22.8 %	36.2 %	54.3 %
	Sodium persulfate)	55.2 %	69.5 %	98.1 %
	Potassium iodate)	84.9 %	93.7 %	100 %

COMPARATIVE EXAMPLE 2EFFECT OF INCREASING RATIO OF PVP:I ON STABILITY

Table 2 shows the effect of increasing the ratio of PVP:I. For all batches hydrogen peroxide was employed as the oxidising agent leaving an excess iodide in the product. All samples were stored at accelerated testing conditions of 55°C.

20 TABLE 2: % AVAILABLE IODINE LOSS AT 55°C

	<u>PVP:I</u>	<u>INITIAL</u>	<u>1 DAY</u>	<u>7 DAYS</u>	<u>14 DAYS</u>
	1.75:1	0.0	4.0	12.3	22.1
	3.50:1	0.0	8.0	24.1	41.1
	5.00:1	0.0	7.8	29.6	44.3
	7.00:1	0.0	8.6	36.2	54.3

COMPARATIVE EXAMPLE 3

The results of these tests show that the ratio of the complexing substance to iodine has no influence on the microbiocidal effectiveness of the iodine complex, provided the available iodine remains the same.

30 Comparison of antimicrobial activity of PVP-I complex of a high and low PVP:I ratio was carried out by the Minimum Inhibitory Concentration (M.I.C.) method

TABLE 3:

<u>TEST ORGANISMS</u>	<u>Culture Count (cfu/ml)</u>
<u>Escherichia coli</u>	6.4×10^9
<u>Staphylococcus aureus</u>	6.3×10^9
<u>Pseudomonas aeruginosa</u>	3.0×10^9
<u>Proteus vulgaris</u>	6.0×10^9

- 7 -

20 μ of the above cultures was inoculated into the test solution.
The test solutions were prepared by making doubling serial dilutions using Difco AOAC medium.

TABLE 4:

RESULT:

PVP:I= 7:1Dilution

<u>Culture</u>	1/25	1/50	1/100	1/200
<u>E. coli</u>	-	-	-	+
<u>S. aureus</u>	-	-	-	-
<u>Ps. aeruginosa</u>	-	-	-	+
<u>P. vulgaris</u>	-	-	-	+

Controls satisfactory.

PVP:I= 1.75:1

<u>E. coli</u>	-	-	-	+
<u>S. aureus</u>	-	-	-	-
<u>Ps. aeruginosa</u>	-	-	-	+
<u>P. vulgaris</u>	-	-	-	+

Controls satisfactory.

The foregoing describes only some embodiments of the present invention
and modifications, obvious to those skilled in the art, can be made thereto
without departing from the scope of the present invention.

- 8 -

BIOCIDAL COMPOSITIONCLAIMS

1. A stable organic iodophor composition comprising an iodophor wherein the ratio of organic iodine solubilizing compound to iodine is less than 5:1 by weight.
2. The composition as claimed in Claim 1 further comprising between 10 and 60% by weight of an iodine liberating substance.
3. The composition as claimed in Claim 1 or Claim 2 wherein the organic iodine solubilizing compound is selected from the group comprising
10 cationic surfactants, non-ionic surfactants, polymers and copolymers.
4. The composition as claimed in Claim 3 wherein the polymer is PVP.
5. The composition as claimed in Claim 3 or Claim 4 wherein the cationic surfactants are quaternary ammonium salts.
6. The composition as claimed in any one of Claims 3 to 5 wherein the non-ionic surfactants have the general formula $RO(CH_2CH_2O)_nOH$ where R is nonylphenol, a fatty acid or fatty alcohol residue and where n is an integer greater than 3.
7. The composition as claimed in any one of Claims 1 to 6 wherein
20 the iodine liberating substance is hydroiodic acid or an alkali metal iodide.
8. The composition as claimed in Claim 7 wherein the alkali metal iodide is potassium iodide.
9. A process for the production of an iodophor composition which process comprises dissolving an organic iodine solubilizing compound and iodine or an iodine liberating substance in water in amounts such that the ratio of iodine liberating substance to iodine is less than 5:1 by weight and optionally adjusting the pH, adding an oxidizing agent and readjusting the pH following oxidation.
10. The process as claimed in Claim 9 wherein when PVP is the
30 organic iodine solubilizing compound, the pH is readjusted to between 3.5 to 5.5.
11. The process as claimed in Claim 9 wherein when a non-ionic surfactant is used as the organic iodine solubilizing compound, the pH is readjusted to below 2.5.
12. The process as claimed in any one of Claims 9 to 11 wherein the oxidizing compounds are peroxides, iodates or persulfates.
13. The process as claimed in Claim 12 wherein the peroxide is

- 9 -


hydrogen peroxide.

14. The process as claimed in Claim 12 wherein the persulfate is selected from the group comprising sodium, potassium or ammonium persulfate.

15. A method for the antiseptic and disinfecting treatment of organic and inert surfaces requiring such treatment, which method comprises treating said surface with an effective amount of the composition of any one of Claims 1 to 9 for a period of time sufficient to effect desired asepsis.

1 / 1


COMPARISON OF ANTISEPTIC SOLUTIONS
WITH VARYING PVP/I RATIOS
40°C STABILITY CURVES



SUBSTITUTE SHEET

INTERNATIONAL SEARCH REPORT

International Application No PCT/AU 88/00234

I. CLASSIFICATION OF SUBJECT MATTER (1) Special Classification symbols (2) IPC Classification symbols (3)		
According to International Patent Classification (IPC) or to both National Classification and IPC Int. Cl. ⁴ A01N 59/12		
II. FIELDS SEARCHED		
Minimum Documentation Searched *		
Classification System	Classification Symbols	
IPC	A01N 59/12, A61K 33/18, A61L 2/18	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched *		
AU : IPC as above		
III. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of Document, ** with indication, where appropriate, of the relevant passages **	Relevant to Claim No. **
X	GB,A, 2084875 (SYNDA CHEMICALS TECHNICAL PROPRIETARY LIMITED) 21 April 1982 (21.04.82) See example	(1,3,4,7-9,15)
X	AU,B, 34918/78 (519505) (MUNDIPHARMA AG) 10 December 1981 (10.12.81) See examples 1,4,5,8,10	(1-15)
P,Y	AU,B, 24643/84 (564632) (EUROCELTIQUE, S.A.) 20 August 1987 (20.08.87) whole document	(1-15)
X	CA,A, 1050382 (GAF CORPORATION) 13 August 1979 (13.08.79)	(1-8,15)
X,Y	US,A, 4151275 (CANTOR et al) 24 April 1979 (24.04.79) See examples 1,2	(1-15)
X	US,A, 4320114 (DENZINGER et al) 16 March 1982 (16.03.82) See claims	(1-11,15)
X	EP,A, 6548 (BASF AKTIENGESELLSCHAFT) 9 January 1980 (09.01.80) See example 1	(1-11,15)
X	AU,B, 87708/75 (493645) (FLOW PHARMACEUTICALS INC) 23 June 1977 (23.06.77) See claims	(1-8,15)
* Special categories of cited documents: ** -A- document defining the general state of the art which is not considered to be of particular relevance -E- earlier document but published on or after the international filing date -L- document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) -O- document referring to an oral disclosure, use, exhibition or other means -P- document published prior to the international filing date but later than the priority date claimed -T- later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention -X- document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step -Y- document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. -A- document member of the same patent family		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search 23 September 1988 (23.09.88)		Date of Mailing of this International Search Report (10-10-88) 10 OCTOBER 1988
International Searching Authority Australian Patent Office		Signature of Authorized Officer  J.P. PULVIRENTI

ANNEX TO THE INTERNATIONAL SEARCH REPORT ON
INTERNATIONAL APPLICATION NO. PCT/AU 88/00234

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report		Patent Family Members	
GB 2084875	ZA 8106812		
AU 34918/78	AT 3476/78 CH 639278 ES 469385 GB 1580596 NL 7803770 PT 67861 ZA 7802026	BE 866395 DE 2821199 FI 780963 IL 54419 NO 781082 SE 7803912	CA 1099728 DK 1407/78 FR 2390963 JP 53148540 NZ 187097 US 4113857
AU 24643/84	DD 221366 EP 120300 ES 8500746 IL 70972 NO 840553 YU 396/84	DE 3313655 EP 120301 FI 840765 IN 159389 NZ 207218 ZA 8401377	DK 1148/84 ES 530184 FI 840765 JP 59202248 PT 78165
AU 87708/75	US 3911107 CA 1055398	US 4031209 DE 2537303	BR 7507504 FR 2366018
US 4151275	CA 1083481	GB 1584282	
US 4320114	CH 603700 GB 1565067	DE 2540170 IT 1069579	FR 2323705 JP 52056190
EP 6548	DE 2827827		

END OF ANNEX